This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
A box of Janssen vaccines is shown by pharmacist Zsolt Szenasi at a warehouse of Hungaropharma, a Hungarian pharmaceutical wholesale company, in Budapest, Hungary, after the arrival of the first batch of the Johnson & Johnson, made one-dose vaccine against the new coronavirus in the country, on April 13, 2021. Szilard Koszticsak/MTI via AP
The European Union’s medicines regulator said on Tuesday that there is a “possible link” between Johnson & Johnson’s COVID-19 vaccine and blood clots, but said its “overall benefit-risk remains positive.”
At a meeting on Tuesday, the safety committee of the European Medicines Agency (EMA) concluded that a warning about unusual blood clots should be added to the product information for COVID-19 Vaccine Janssen, which was developed by Janssen, a subsidiary of Johnson & Johnson.
